Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $158.77 billion. The enterprise value is $170.15 billion.
| Market Cap | 158.77B |
| Enterprise Value | 170.15B |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | Jun 15, 2026 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has decreased by -0.34% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | -0.34% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 88.53% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 17.39 and the forward PE ratio is 69.82.
| PE Ratio | 17.39 |
| Forward PE | 69.82 |
| PS Ratio | 5.34 |
| Forward PS | 5.16 |
| PB Ratio | 6.75 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 15.52 |
| P/OCF Ratio | 14.69 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.54, with an EV/FCF ratio of 16.63.
| EV / Earnings | 18.46 |
| EV / Sales | 5.72 |
| EV / EBITDA | 11.54 |
| EV / EBIT | 14.20 |
| EV / FCF | 16.63 |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.95.
| Current Ratio | 1.97 |
| Quick Ratio | 1.54 |
| Debt / Equity | 0.95 |
| Debt / EBITDA | 1.49 |
| Debt / FCF | 2.17 |
| Interest Coverage | 11.94 |
Financial Efficiency
Return on equity (ROE) is 43.36% and return on invested capital (ROIC) is 27.70%.
| Return on Equity (ROE) | 43.36% |
| Return on Assets (ROA) | 13.29% |
| Return on Invested Capital (ROIC) | 27.70% |
| Return on Capital Employed (ROCE) | 25.61% |
| Weighted Average Cost of Capital (WACC) | 5.81% |
| Revenue Per Employee | $1.75M |
| Profits Per Employee | $542,118 |
| Employee Count | 17,000 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 3.34 |
Taxes
In the past 12 months, Gilead Sciences has paid $1.51 billion in taxes.
| Income Tax | 1.51B |
| Effective Tax Rate | 14.09% |
Stock Price Statistics
The stock price has increased by +20.72% in the last 52 weeks. The beta is 0.33, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +20.72% |
| 50-Day Moving Average | 130.31 |
| 200-Day Moving Average | 129.67 |
| Relative Strength Index (RSI) | 50.27 |
| Average Volume (20 Days) | 9,890,641 |
Short Selling Information
The latest short interest is 23.86 million, so 1.92% of the outstanding shares have been sold short.
| Short Interest | 23.86M |
| Short Previous Month | 25.73M |
| Short % of Shares Out | 1.92% |
| Short % of Float | 1.93% |
| Short Ratio (days to cover) | 3.02 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $29.74 billion and earned $9.22 billion in profits. Earnings per share was $7.35.
| Revenue | 29.74B |
| Gross Profit | 23.60B |
| Operating Income | 11.99B |
| Pretax Income | 10.73B |
| Net Income | 9.22B |
| EBITDA | 14.74B |
| EBIT | 11.99B |
| Earnings Per Share (EPS) | $7.35 |
Balance Sheet
The company has $9.82 billion in cash and $22.17 billion in debt, giving a net cash position of -$11.37 billion or -$9.16 per share.
| Cash & Cash Equivalents | 9.82B |
| Total Debt | 22.17B |
| Net Cash | -11.37B |
| Net Cash Per Share | -$9.16 |
| Equity (Book Value) | 23.43B |
| Book Value Per Share | 18.93 |
| Working Capital | 9.17B |
Cash Flow
In the last 12 months, operating cash flow was $10.81 billion and capital expenditures -$576.00 million, giving a free cash flow of $10.23 billion.
| Operating Cash Flow | 10.81B |
| Capital Expenditures | -576.00M |
| Depreciation & Amortization | 2.75B |
| Net Borrowing | -2.79B |
| Free Cash Flow | 10.23B |
| FCF Per Share | $8.24 |
Margins
Gross margin is 79.37%, with operating and profit margins of 40.30% and 30.99%.
| Gross Margin | 79.37% |
| Operating Margin | 40.30% |
| Pretax Margin | 36.07% |
| Profit Margin | 30.99% |
| EBITDA Margin | 49.56% |
| EBIT Margin | 40.30% |
| FCF Margin | 34.40% |
Dividends & Yields
This stock pays an annual dividend of $3.28, which amounts to a dividend yield of 2.65%.
| Dividend Per Share | $3.28 |
| Dividend Yield | 2.65% |
| Dividend Growth (YoY) | 3.21% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 43.79% |
| Buyback Yield | 0.34% |
| Shareholder Yield | 2.90% |
| Earnings Yield | 5.80% |
| FCF Yield | 6.44% |
Analyst Forecast
The average price target for Gilead Sciences is $157.57, which is 23.22% higher than the current price. The consensus rating is "Buy".
| Price Target | $157.57 |
| Price Target Difference | 23.22% |
| Analyst Consensus | Buy |
| Analyst Count | 30 |
| Revenue Growth Forecast (3Y) | 5.14% |
| EPS Growth Forecast (3Y) | 8.72% |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 4.51 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.51 |
| Piotroski F-Score | 8 |